Skip to search formSkip to main contentSkip to account menu

PKI 587

Known as: PKI-587, PKI587 
National Institutes of Health

Related topics

Related topics

1 relation
PF-05212384

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 325: Pediatric relapsed acute lymphoblastic leukemia patients display enrichment of the PI3K/mTOR pathway and respond to the dual PI3K/mTOR inhibitor PKI-587
2016
2016
Supplementary Material for: Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease
2015
2015
Genomic analysis of PI3K/AKT/mTOR pathway in mesothelioma and treatment of mesothelioma cell lines in vitro using PI3K/mTOR inhibitor PKI-587
Mesothelioma is an aggressive cancer that develops from mesothelial cells, the protective cells that cover many internal organs1… 
2015
2015
First-in-HumanStudyofPF-05212384 ( PKI-587 ) , a Small-Molecule , Intravenous , Dual Inhibitor of PI 3 K and mTOR in Patients with Advanced Cancer
Purpose: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity… 
2015
2015
Abstract 670: Targeting PI3K/mTOR leads to MEK/ERK over-activation in pancreatic cancer through suppression of mTORC2
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Significant attention has been given to… 
2015
2015
Abstract A109: Dual mTOR/PI3K inhibitors induce compensatory MEK/ERK activation in human pancreatic cancer cells: A mechanism contributing to drug resistance
Background: The phosphatidylinositol 3-kinase (PI3K)/Akt/mTORC1/S6K pathway is aberrantly activated in premalignant pancreatic… 
2014
2014
Abstract 3951: Dual phosphoinositide 3-kinase/Mammalian target of rapamycin inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma
Purpose Although combined chemo-radiotherapy has provided considerable improvements for nasopharyngeal carcinoma (NPC… 
2014
2014
Exploring Therapeutic Targets in Schwannoma Through Integrative Analysis
Vestibular schwannomas (VS) are common benign tumors of the vestibular nerve and spinal schwannomas (SS) arise form nerves within… 
2011
2011
Cancer Therapy : Preclinical Antitumor Efficacy of PKI-587 , a Highly Potent Dual PI 3 K / mTOR Kinase Inhibitor
Purpose: The aim of this study was to show preclinical efficacy and clinical development potential of PKI-587, a dual… 
2010
2010
Abstract 723: Beyond temsirolimus: Discovery of PKI-587 a highly efficacious dual PI3K/mTOR inhibitor
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Temsirolimus, a rapamycin analog, is a selective… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)